Intercept Pharma Slips 28% As FDA Panel Votes Against Liver Disease Drug
Intercept Pharmaceutics, Inc (ICPT) shares are down almost 28% on Monday, after an FDA advisory panel voted against Intercept's drug obeticholic acid for the treatment of nonalcoholic steatohepatitis, or NASH.
Gastrointestinal Drugs Advisory Committee Intercept Pharmaceutics Inc Intercept Pharmaceutics Drugs Advisory Committee Prescription Drug User Fee Act Target Action Date
Source: rttnews.com